Selective elimination of synovial inflammatory macrophages in rheumatoid arthritis by an Fcγ receptor I-directed immunotoxin

Arthritis and Rheumatism

Volumn 48, Issue 5, 2003, Pages 1229-1238

  Van Roon, Joel A G ^a   Van Vuuren, Anneke J ^a   Wijngaarden, Siska ^a   Jacobs, Kim M G ^a   Bijlsma, Johannes W J ^a   Lafeber, Floris P J G ^a   Thepen, Theo ^b   Van de Winkel, Jan G J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MEDAREX INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD64 ANTIGEN; DNA FRAGMENT; FC RECEPTOR; IMMUNOTOXIN; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY; RICIN A; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTHRITIS; ARTICLE; CARTILAGE DEGENERATION; CELL DEATH; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOCYTOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; SYNOVIAL MACROPHAGE; SYNOVIUM; TISSUE CULTURE;

AGED; AGED, 80 AND OVER; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; APOPTOSIS; ARTHRITIS, RHEUMATOID; CELL DEATH; CELLS, CULTURED; ENDOCYTOSIS; HUMANS; IMMUNOTOXINS; MACROPHAGE ACTIVATION; MACROPHAGES; MIDDLE AGED; OUTPATIENTS; RECEPTORS, IGG; RICIN; SYNOVIAL FLUID; SYNOVIAL MEMBRANE;

EID: 0037653345     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10940     Document Type: Article

References (38)

1. Burmester GR, Stuhlmüller B, Keyszer G, Kinne RW. Mononuclear phagocytes and rheumatoid synovitis: mastermind or workhorse in arthritis? Arthritis Rheum 1997;40:5-18.
2. Mulherin D, FitzGerald O, Bresnihan B. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum 1996;39:115-24.
3. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
4. Bresnihan B. The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 2001;30 Suppl 2:17-20.
5. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
6. Miossec P, Chomarat P, Dechanet J. Bypassing the antigen to control rheumatoid arthritis. Immunol Today 1996;17:170-3.
7. Van Roon JA, Lafeber FP, Bijlsma JW. Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis. Arthritis Rheum 2001;44:3-12.
8. Albani S, Keystone EC, Nelson JL, Ollier WE, La Cava A, Montemayor AC, et al. Positive selection in autoimmunity: abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis. Nat Med 1995;1: 448-52.
9. Choy EH, Pitzalis C, Cauli A, Bijl JA, Schantz A, Woody J, et al. Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement: implications for the development of immunotherapeutic dosing regimens. Arthritis Rheum 1996;39:52-6.
10. Hahn G, Stuhlmüller B, Hain N, Kalden JR, Pfizenmaier K, Burmester GR. Modulation of monocyte activation in patients with rheumatoid arthritis by leukapheresis therapy. J Clin Invest 1993;91:862-70.
11. Hidaka T, Suzuki K, Matsuki Y, Takamizawa-Matsumoto M, Kataharada K, Ishizuka T, et al. Filtration leukocytapheresis therapy in rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1999;42:431-7.
12. Barrera P, Blom A, van Lent PLEM, van Bloois L, Beijnen JH, van Rooijen N, et al. Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum 2000;43:1951-9.
13. Deo YM, Graziano RF, Repp R, van de Winkel JG. Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies. Immunol Today 1997;18:127-35.
14. Te Velde AA, de Waal MR, Huijbens RJ, de Vries JE, Figdor CG. IL-10 stimulates monocyte FcγR surface expression and cytotoxic activity: distinct regulation of antibody-dependent cellular cytotoxicity by IFN-γ, IL-4, and IL-10. J Immunol 1992;149:4048-52.
15. Heijnen IA, van Vugt MJ, Fanger NA, Graziano RF, de Wit TP, Hofhuis FM, et al. Antigen targeting to myeloid-specific human FcγRI/CD64 triggers enhanced antibody responses in transgenic mice. J Clin Invest 1996;97:331-8.
16. Liu C, Goldstein J, Graziano RF, He J, O'Shea JK, Deo Y, et al. F(c)-γRI-targeted fusion proteins result in efficient presentation by human monocytes of antigenic and antagonist T cell epitopes. J Clin Invest 1996;98:2001-7.
17. Thrush GR, Lark LR, Clinchy BC, Vitetta ES. Immunotoxins: an update. Annu Rev Immunol 1996;14:49-71.
18. Vitetta ES, Krolick KA, Miyama-Inaba M, Cushley W, Uhr JW. Immunotoxins: a new approach to cancer therapy. Science 1983; 219:644-50.
19. Thepen T, van Vuuren AJ, Kiekens RC, Damen CA, Vooijs WC, van de Winkel JG. Resolution of cutaneous inflammation after local elimination of macrophages. Nat Biotechnol 2000;18:48-51.
20. Zhong RK, van de Winkel JG, Thepen T, Schultz LD, Ball ED. Cytotoxicity of anti-CD64-ricin a chain immunotoxin against human acute myeloid leukemia cells in vitro and in SCID mice. J Hematother Stem Cell Res 2001;10:95-105.
21. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
22. Heidenreich S, Schmidt M, August C, Cullen P, Rademaekers A, Pauels HG. Regulation of human monocyte apoptosis by the CD14 molecule. J Immunol 1997;159:3178-88.
23. Koester SK, Schlossman SF, Zhang C, Decker SJ, Bolton WE. APO2.7 defines a shared apoptotic-necrotic pathway in a breast tumor hypoxia model. Cytometry 1998;33:324-32.
24. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9.
25. Van Roon JA, van Roy JL, Duits A, Lafeber FP, Bijlsma JW. Proinflammatory cytokine production and cartilage damage due to rheumatoid synovial T helper-1 activation is inhibited by interleukin-4. Ann Rheum Dis 1995;54:836-40.
26. Felzmann T, Gadd S, Majdic O, Maurer D, Petera P, Smolen J, et al. Analysis of function-associated receptor molecules on peripheral blood and synovial fluid granulocytes from patients with rheumatoid and reactive arthritis. J Clin Immunol 1991;11:205-12.
27. Highton J, Carlisle B, Palmer DG. Changes in the phenotype of monocytes/macrophages and expression of cytokine mRNA in peripheral blood and synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol 1995;102:541-6.
28. Quayle JA, Watson F, Bucknall RC, Edwards SW. Neutrophils from the synovial fluid of patients with rheumatoid arthritis express the high affinity immunoglobulin G receptor, FcγRI (CD64): role of immune complexes and cytokines in induction of receptor expression. Immunology 1997;91:266-73.
29. Heidenreich S. Monocyte CD14: a multifunctional receptor engaged in apoptosis from both sides. J Leukoc Biol 1999;65:737-43.
30. Perlman H, Pagliari LJ, Liu H, Koch AE, Haines GK III, Pope RM. Rheumatoid arthritis synovial macrophages express the Fas-associated death domain-like interleukin-1β-converting enzyme-inhibitory protein and are refractory to Fas-mediated apoptosis. Arthritis Rheum 2001;44:21-30.
31. Van Roon JA, van Eden W, van Roy JL, Lafeber FJ, Bijlsma JW. Stimulation of suppressive T cell responses by human but not bacterial 60-kD heat-shock protein in synovial fluid of patients with rheumatoid arthritis. J Clin Invest 1997;100:459-63.
32. Ounissi-Benkalha H, Pelletier J-P, Tardif G, Mineau F, Jolicoeur FC, Ranger P, et al. In vitro effects of 2 antirheumatic drugs on the synthesis and expression of proinflammatory cytokines in synovial membranes from patients with rheumatoid arthritis. J Rheumatol 1996;23:16-23.
33. Broker BM, Edwards JC, Fanger MW, Lydyard PM. The prevalence and distribution of macrophages bearing Fc gamma R I, Fc gamma R II, and Fc gamma R III in synovium. Scand J Rheumatol 1990;19:123-35.
34. Wilbrink B, Nietfeld JJ, den Otter W, van Roy JL, Bijlsma JW, Huber-Bruning O. Role of TNF alpha, in relation to IL-1 and IL-6 in the proteoglycan turnover of human articular cartilage. Br J Rheumatol 1991;30:265-71.
35. Hardingham T, Bayliss M. Proteoglycans of articular cartilage: changes in aging and in joint disease. Semin Arthritis Rheum 1990;20 Suppl 1:12-33.
36. Lanzavecchia A. Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes. Annu Rev Immunol 1990;8:773-93.
37. Van Lent PL, Van den Hoek AE, Van den Bersselaar LA, Spanjaards MF, van Rooijen N, Dijkstra CD, et al. In vivo role of phagocytic synovial lining cells in onset of experimental arthritis. Am J Pathol 1993;143:1226-37.
38. McCormick TS, Stevens SR, Kang K. Macrophages and cutaneous inflammation. Nat Biotechnol 2000;18:25-6.